United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis

Jan M. Griffin; Leonard Chiu; Kelly M. Axsom; Rachel Bijou; Kevin J. Clerkin; Paolo Colombo; Margaret O. Cuomo; Jeffeny De Los Santos; Justin A. Fried; Jeff Goldsmith; Marlena Habal; Jennifer Haythe; Stephen Helmke; Evelyn M. Horn; Farhana Latif; Sun Hi Lee; Edward F. Lin; Yoshifumi Naka; Jayant Raikhelkar; Susan Restaino; Gabriel T. Sayer; Hiroo Takayama; Koji Takeda; Sergio Teruya; Veli Topkara; Emily J. Tsai; Nir Uriel; Melana Yuzefpolskaya; Maryjane A. Farr; Mathew S. Maurer

doi:10.1111/ctr.14028

United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis

Jan M. Griffin, Leonard Chiu, Kelly M. Axsom, Rachel Bijou, Kevin J. Clerkin, Paolo Colombo, Margaret O. Cuomo, Jeffeny De Los Santos, Justin A. Fried, Jeff Goldsmith, Marlena Habal, Jennifer Haythe, Stephen Helmke, Evelyn M. Horn, Farhana Latif, Sun Hi Lee, Edward F. Lin, Yoshifumi Naka, Jayant Raikhelkar, Susan RestainoGabriel T. Sayer, Hiroo Takayama, Koji Takeda, Sergio Teruya, Veli Topkara, Emily J. Tsai, Nir Uriel, Melana Yuzefpolskaya, Maryjane A. Farr, Mathew S. Maurer

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Light-chain (AL) cardiac amyloidosis (CA) has a worse prognosis than transthyretin (ATTR) CA. In this single-center study, we compared post-heart transplant (OHT, orthotopic heart transplantation) survival for AL and ATTR amyloidosis, hypothesizing that these differences would persist post-OHT. Thirty-nine patients with CA (AL, n = 18; ATTR, n = 21) and 1023 non-amyloidosis subjects undergoing OHT were included. Cox proportional hazards modeling was used to evaluate the impact of amyloid subtype and era (early era: from 2001 to 2007; late era: from 2008 to 2018) on survival post-OHT. Survival for non-amyloid patients was greater than ATTR (P =.034) and AL (P <.001) patients in the early era. One, 3-, and 5-year survival rates were higher for ATTR patients than AL patients in the early era (100% vs 75%, 67% vs 50%, and 67% vs 33%, respectively, for ATTR and AL patients). Survival in the non-amyloid cohort was 87% at 1 year, 81% at 3 years, and 76% at 5 years post-OHT. In the late era, AL and ATTR patients had unadjusted 1-year, 3-year, and 5-year survival rates of 100%, which was comparable to non-amyloid patients (90% vs 84% vs 81%). Overall, these findings demonstrate that in the current era, differences in post-OHT survival for AL compared to ATTR are diminishing; OHT outcomes for selected patients with CA do not differ from non-amyloidosis patients.

Original language	English (US)
Article number	e14028
Journal	Clinical Transplantation
Volume	34
Issue number	10
DOIs	https://doi.org/10.1111/ctr.14028
State	Published - Oct 1 2020
Externally published	Yes

Keywords

amyloid
cardiomyopathy
heart transplant
light-chain
transthyretin

ASJC Scopus subject areas

Transplantation

Access to Document

10.1111/ctr.14028

Cite this

Griffin, J. M., Chiu, L., Axsom, K. M., Bijou, R., Clerkin, K. J., Colombo, P., Cuomo, M. O., De Los Santos, J., Fried, J. A., Goldsmith, J., Habal, M., Haythe, J., Helmke, S., Horn, E. M., Latif, F., Hi Lee, S., Lin, E. F., Naka, Y., Raikhelkar, J., ... Maurer, M. S. (2020). United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis. Clinical Transplantation, 34(10), Article e14028. https://doi.org/10.1111/ctr.14028

Griffin, JM, Chiu, L, Axsom, KM, Bijou, R, Clerkin, KJ, Colombo, P, Cuomo, MO, De Los Santos, J, Fried, JA, Goldsmith, J, Habal, M, Haythe, J, Helmke, S, Horn, EM, Latif, F, Hi Lee, S, Lin, EF, Naka, Y, Raikhelkar, J, Restaino, S, Sayer, GT, Takayama, H, Takeda, K, Teruya, S, Topkara, V, Tsai, EJ, Uriel, N, Yuzefpolskaya, M, Farr, MA & Maurer, MS 2020, 'United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis', Clinical Transplantation, vol. 34, no. 10, e14028. https://doi.org/10.1111/ctr.14028

@article{d757cc75771945d69bcf66f46655a114,

title = "United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis",

abstract = "Light-chain (AL) cardiac amyloidosis (CA) has a worse prognosis than transthyretin (ATTR) CA. In this single-center study, we compared post-heart transplant (OHT, orthotopic heart transplantation) survival for AL and ATTR amyloidosis, hypothesizing that these differences would persist post-OHT. Thirty-nine patients with CA (AL, n = 18; ATTR, n = 21) and 1023 non-amyloidosis subjects undergoing OHT were included. Cox proportional hazards modeling was used to evaluate the impact of amyloid subtype and era (early era: from 2001 to 2007; late era: from 2008 to 2018) on survival post-OHT. Survival for non-amyloid patients was greater than ATTR (P =.034) and AL (P <.001) patients in the early era. One, 3-, and 5-year survival rates were higher for ATTR patients than AL patients in the early era (100% vs 75%, 67% vs 50%, and 67% vs 33%, respectively, for ATTR and AL patients). Survival in the non-amyloid cohort was 87% at 1 year, 81% at 3 years, and 76% at 5 years post-OHT. In the late era, AL and ATTR patients had unadjusted 1-year, 3-year, and 5-year survival rates of 100%, which was comparable to non-amyloid patients (90% vs 84% vs 81%). Overall, these findings demonstrate that in the current era, differences in post-OHT survival for AL compared to ATTR are diminishing; OHT outcomes for selected patients with CA do not differ from non-amyloidosis patients.",

keywords = "amyloid, cardiomyopathy, heart transplant, light-chain, transthyretin",

author = "Griffin, {Jan M.} and Leonard Chiu and Axsom, {Kelly M.} and Rachel Bijou and Clerkin, {Kevin J.} and Paolo Colombo and Cuomo, {Margaret O.} and {De Los Santos}, Jeffeny and Fried, {Justin A.} and Jeff Goldsmith and Marlena Habal and Jennifer Haythe and Stephen Helmke and Horn, {Evelyn M.} and Farhana Latif and {Hi Lee}, Sun and Lin, {Edward F.} and Yoshifumi Naka and Jayant Raikhelkar and Susan Restaino and Sayer, {Gabriel T.} and Hiroo Takayama and Koji Takeda and Sergio Teruya and Veli Topkara and Tsai, {Emily J.} and Nir Uriel and Melana Yuzefpolskaya and Farr, {Maryjane A.} and Maurer, {Mathew S.}",

note = "Publisher Copyright: {\textcopyright} 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/ctr.14028",

language = "English (US)",

volume = "34",

journal = "Clinical Transplantation",

issn = "0902-0063",

publisher = "Wiley-Blackwell",

number = "10",

}

TY - JOUR

T1 - United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis

AU - Griffin, Jan M.

AU - Chiu, Leonard

AU - Axsom, Kelly M.

AU - Bijou, Rachel

AU - Clerkin, Kevin J.

AU - Colombo, Paolo

AU - Cuomo, Margaret O.

AU - De Los Santos, Jeffeny

AU - Fried, Justin A.

AU - Goldsmith, Jeff

AU - Habal, Marlena

AU - Haythe, Jennifer

AU - Helmke, Stephen

AU - Horn, Evelyn M.

AU - Latif, Farhana

AU - Hi Lee, Sun

AU - Lin, Edward F.

AU - Naka, Yoshifumi

AU - Raikhelkar, Jayant

AU - Restaino, Susan

AU - Sayer, Gabriel T.

AU - Takayama, Hiroo

AU - Takeda, Koji

AU - Teruya, Sergio

AU - Topkara, Veli

AU - Tsai, Emily J.

AU - Uriel, Nir

AU - Yuzefpolskaya, Melana

AU - Farr, Maryjane A.

AU - Maurer, Mathew S.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Light-chain (AL) cardiac amyloidosis (CA) has a worse prognosis than transthyretin (ATTR) CA. In this single-center study, we compared post-heart transplant (OHT, orthotopic heart transplantation) survival for AL and ATTR amyloidosis, hypothesizing that these differences would persist post-OHT. Thirty-nine patients with CA (AL, n = 18; ATTR, n = 21) and 1023 non-amyloidosis subjects undergoing OHT were included. Cox proportional hazards modeling was used to evaluate the impact of amyloid subtype and era (early era: from 2001 to 2007; late era: from 2008 to 2018) on survival post-OHT. Survival for non-amyloid patients was greater than ATTR (P =.034) and AL (P <.001) patients in the early era. One, 3-, and 5-year survival rates were higher for ATTR patients than AL patients in the early era (100% vs 75%, 67% vs 50%, and 67% vs 33%, respectively, for ATTR and AL patients). Survival in the non-amyloid cohort was 87% at 1 year, 81% at 3 years, and 76% at 5 years post-OHT. In the late era, AL and ATTR patients had unadjusted 1-year, 3-year, and 5-year survival rates of 100%, which was comparable to non-amyloid patients (90% vs 84% vs 81%). Overall, these findings demonstrate that in the current era, differences in post-OHT survival for AL compared to ATTR are diminishing; OHT outcomes for selected patients with CA do not differ from non-amyloidosis patients.

AB - Light-chain (AL) cardiac amyloidosis (CA) has a worse prognosis than transthyretin (ATTR) CA. In this single-center study, we compared post-heart transplant (OHT, orthotopic heart transplantation) survival for AL and ATTR amyloidosis, hypothesizing that these differences would persist post-OHT. Thirty-nine patients with CA (AL, n = 18; ATTR, n = 21) and 1023 non-amyloidosis subjects undergoing OHT were included. Cox proportional hazards modeling was used to evaluate the impact of amyloid subtype and era (early era: from 2001 to 2007; late era: from 2008 to 2018) on survival post-OHT. Survival for non-amyloid patients was greater than ATTR (P =.034) and AL (P <.001) patients in the early era. One, 3-, and 5-year survival rates were higher for ATTR patients than AL patients in the early era (100% vs 75%, 67% vs 50%, and 67% vs 33%, respectively, for ATTR and AL patients). Survival in the non-amyloid cohort was 87% at 1 year, 81% at 3 years, and 76% at 5 years post-OHT. In the late era, AL and ATTR patients had unadjusted 1-year, 3-year, and 5-year survival rates of 100%, which was comparable to non-amyloid patients (90% vs 84% vs 81%). Overall, these findings demonstrate that in the current era, differences in post-OHT survival for AL compared to ATTR are diminishing; OHT outcomes for selected patients with CA do not differ from non-amyloidosis patients.

KW - amyloid

KW - cardiomyopathy

KW - heart transplant

KW - light-chain

KW - transthyretin

UR - http://www.scopus.com/inward/record.url?scp=85088391067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088391067&partnerID=8YFLogxK

U2 - 10.1111/ctr.14028

DO - 10.1111/ctr.14028

M3 - Article

C2 - 32623785

AN - SCOPUS:85088391067

SN - 0902-0063

VL - 34

JO - Clinical Transplantation

JF - Clinical Transplantation

IS - 10

M1 - e14028

ER -

United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this